









Markets
/
Stocks
/
nasdaq-sava
/

Cassava Sciences Inc

SAVA

2.380USD

0.0000.00%

Market hours （ET）Quotes delayed by 15 min

15.21MMarket Cap

LossP/E TTM



Cassava Sciences Inc

2.380

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cassava Sciences Inc

Currency: USD Updated: 2026-03-10

Key Insights

Cassava Sciences Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cassava Sciences Inc's Score

Industry at a Glance

Industry Ranking

142 / 388

Overall Ranking

251 / 4485

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Cassava Sciences Inc Highlights

StrengthsRisks

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Overvalued

The company’s latest PE is -1.07, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 14.09M shares, decreasing 15.71% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.38M shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

5.000

Target Price

+110.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-10

The current financial score of Cassava Sciences Inc is 6.90, ranking 187 out of 388 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.90

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cassava Sciences Inc's Company Valuation

Currency: USD Updated: 2026-03-10

The current valuation score of Cassava Sciences Inc is 7.94, ranking 72 out of 388 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.07, which is -35.67% below the recent high of -0.69 and -7956.17% above the recent low of -86.34.

Score

Industry at a Glance

Previous score

7.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/388

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-10

The current earnings forecast score of Cassava Sciences Inc is 8.00, ranking 159 out of 388 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 8.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

5.000

Target Price

+110.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Cassava Sciences Inc

SAVA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-10

The current price momentum score of Cassava Sciences Inc is 5.76, ranking 309 out of 388 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.59 and the support level at 2.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.92

Change

0.84

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Buy

RSI(14)

58.060

Neutral

STOCH(KDJ)(9,3,3)

52.173

Buy

ATR(14)

0.162

High Vlolatility

CCI(14)

98.451

Neutral

Williams %R

20.755

Buy

TRIX(12,20)

0.223

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.156

Buy

MA10

2.221

Buy

MA20

2.191

Buy

MA50

2.121

Buy

MA100

2.650

Sell

MA200

2.515

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-10

The latest institutional shareholding proportion is 29.17%, representing a quarter-over-quarter increase of 16.69%. The largest institutional shareholder is The Vanguard, holding a total of 2.38M shares, representing 4.92% of shares outstanding, with 2.73% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

2.29M

+5.50%

Nachtrab (Matthew)

2.27M

Marshall Wace LLP

2.06M

+2774.31%

Barbier (Remi)

2.07M

+54.36%

Two Sigma Investments, LP

1.53M

+1.08%

BlackRock Institutional Trust Company, N.A.

1.40M

-7.93%

Geode Capital Management, L.L.C.

537.90K

+2.87%

Susquehanna International Group, LLP

382.02K

-14.43%

Barry (Richard J)

469.56K

+33.33%

Risk Assessment

Currency: USD Updated: 2026-03-10

Cassava Sciences Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.